ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Bianchi, G ^a   Vuerich, M ^b   Pellegatti, P ^b,c   Marimpietri, D ^a   Emionite, L ^d   Marigo, I ^e   Bronte, V ^f   Di Virgilio, F ^b   Pistoia, V ^a   Raffaghello, L ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

ATP; Myeloid derived suppressor cells; Neuroblastoma; P2X7 receptor; Purinergic receptors

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGINASE 1; CD11B ANTIGEN; PURINERGIC P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTOTOXICITY; MONONUCLEAR PHAGOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEUROBLASTOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, CD11B; ARGINASE; CELL LINE, TUMOR; CYTOKINES; FEMALE; HEK293 CELLS; HUMANS; MICE; MYELOID CELLS; NEUROBLASTOMA; REACTIVE OXYGEN SPECIES; RECEPTORS, CHEMOKINE; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84897428048     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.109     Document Type: Article

References (63)

1. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912.
2. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
3. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271.
4. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
5. Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72: 5441-5447.
6. Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal 2012; 9: 145-165.
7. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29: 5346-5358.
8. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 2008; 10: 987-995.
9. Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D et al. Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 2009; 284: 10120-10128.
10. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
11. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
12. Di Virgilio F, Boeynaems JM, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009; 9: 507-513.
13. Di Virgilio F, Ferrari D, Adinolfi E. P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 2009; 5: 251-256.
14. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 2005; 16: 3260-3272.
15. Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V. The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res 2006; 66: 907-914.
16. Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D, Sanz JM, Venketaraman V et al. Cytolytic P2X purinoceptors. Cell Death Differ 1998; 5: 191-199.
17. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G et al. Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 1999; 274: 33206-33208.
18. Hanley PJ, Kronlage M, Kirschning C, del Rey A, Di Virgilio F, Leipziger J et al. Transient P2X7 receptor activation triggers macrophage death independent of Toll-like receptors 2 and 4, caspase-1, and pannexin-1 proteins. J Biol Chem 2012; 287: 10650-10663.
19. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13: 343-351.
20. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006; 176: 3877-3883.
21. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
23. Santilli G, Piotrowska I, Cantilena S, Chayka O, D'Alicarnasso M, Morgenstern DA et al. Polyphenol e enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res 2013; 19: 1116-1125.
24. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40: 22-35.
25. Rayah A, Kanellopoulos JM, Di Virgilio F. P2 receptors and immunity. Microbes Infect 2012; 14: 1254-1262.
26. Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001; 276: 3820-3826.
27. Di Virgilio F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today 1995; 16: 524-528.
28. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 2000; 165: 6723-6730.
29. Greenberg S, Di Virgilio F, Steinberg TH, Silverstein SC. Extracellular nucleotides mediate Ca2+ fluxes in J774 macrophages by two distinct mechanisms. J Biol Chem 1988; 263: 10337-10343.
30. Khakh BS, North RA. Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 2012; 76: 51-69.
31. Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev 2013; 65: 872-905.
32. Tu MT, Luo SF, Wang CC, Chien CS, Chiu CT, Lin CC et al. P2Y(2) receptor-mediated proliferation of C(6) glioma cells via activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 2000; 129: 1481-1489.
33. Gerasimovskaya EV, Woodward HN, Tucker DA, Stenmark KR. Extracellular ATP is a proangiogenic factor for pulmonary artery vasa vasorum endothelial cells. Angiogenesis 2008; 11: 169-182.
34. Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di Virgilio F. The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J Clin Invest 1995; 95: 1207-1216.
35. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996; 272: 735-738.
36. Ferrari D, Los M, Bauer MK, Vandenabeele P, Wesselborg S, Schulze-Osthoff K. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett 1999; 447: 71-75.
37. Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002; 99: 706-708.
38. Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 2004; 44: 206-215.
39. Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG et al. Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 2008; 149: 389-396.
40. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P et al. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 2012; 72: 2957-2969.
41. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008; 3: e2599.
42. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-3728.
43. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
44. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010; 139: 1030-1040.
45. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
46. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-3846.
47. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166: 5398-5406.
48. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743-11751.
49. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
50. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
51. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
52. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007; 109: 4336-4342.
53. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S et al. Myeloidderived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-244.
54. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
55. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
56. Hammami I, Chen J, Bronte V, De Crescenzo G, Jolicoeur M. Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. J Biotechnol 2011; 152: 43-48.
57. Foster JG, Carter E, Kilty I, MacKenzie AB, Ward SG. Mitochondrial superoxide generation enhances P2X7R-mediated loss of cell surface CD62L on naive human CD4+ T lymphocytes. J Immunol 2013; 190: 1551-1559.
58. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004; 14: 149-154.
59. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004; 199: 1213-1221.
60. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949-1962.
61. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+ Gr1+ cells. J Immunol 2011; 187: 6120-6129.
62. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997; 89: 1586-1594.
63. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 2005; 16: 3659-3665.